← Back to book summaries

Summary of "The Emperor of All Maladies"

Summary of "The Emperor of All Maladies"

Introduction

Siddhartha Mukherjee's Pulitzer Prize-winning book traces the complex history of cancer and humanity's evolving battle against it. Through intertwining scientific breakthroughs, political movements, and personal narratives, Mukherjee presents cancer not simply as a disease but as a character with its own biography—resilient, adaptive, and deeply intertwined with human genetics.

The Historical Arc of Cancer

Ancient Beginnings

Cancer has shadowed humanity throughout history, though often overshadowed by infectious diseases. Early descriptions date back to Ancient Egypt (2500 BCE) when Imhotep described breast tumors, noting there was "no treatment" available. Cancer remained relatively uncommon in ancient societies primarily because people didn't live long enough to develop it—they died from other causes first.

Evolving Understanding

Our comprehension of cancer has undergone several paradigm shifts:

  1. Humoral Theory: For 1,500 years, Galen's idea that cancer resulted from an excess of "black bile" dominated medical thinking.
  2. Anatomical Revolution: The humoral theory gradually declined as anatomists like Andreas Vesalius could find no evidence of black bile.
  3. Cellular Theory: Rudolf Virchow revolutionized understanding in the 1840s by proposing cancer was a cellular disease—normal cells dividing uncontrollably.
  4. Genetic Revolution: The discovery that cancer originates from mutations in our own genes transformed our understanding once again. Scientists identified two critical types of genes involved:
    • Oncogenes (accelerate cell growth when activated)
    • Tumor suppressor genes (prevent excessive growth when functioning normally)
  5. Comprehensive Genetic Mapping: The Cancer Genome Atlas project revealed that common cancers typically contain 40-80 mutations affecting about 13 core cellular pathways.

The Evolution of Treatment

Radical Surgery

William Halsted pioneered the radical mastectomy in the 1890s, removing not just the breast but underlying muscles and lymph nodes. His aggressive approach dominated cancer treatment for nearly a century despite limited evidence of improved survival.

Radiation Therapy

The discovery of X-rays by Wilhelm Röntgen (1895) and radium by the Curies (1902) introduced radiation as a powerful tool against cancer—though one with serious side effects. Marie Curie herself later died of leukemia caused by radiation exposure.

Chemotherapy's Birth

Sidney Farber began treating children with acute lymphoblastic leukemia using antifolate drugs in 1947. His first patient to respond, Robert Sandler, demonstrated the potential of chemicals to fight cancer.

Researchers at the National Cancer Institute developed combination chemotherapy in the 1950s and 1960s. The VAMP protocol (Vincristine, Amethopterin, Mercaptopurine, and Prednisone) produced the first cures of childhood leukemia—establishing that cancer could potentially be cured with drugs.

Targeted Therapies

By understanding specific genetic mutations in cancers, researchers developed precision treatments:

  1. Gleevec (imatinib): Developed by Brian Druker for chronic myeloid leukemia, targeting the BCR-ABL fusion protein. When patients received Gleevec, many experienced complete remissions, turning a previously fatal disease into a manageable condition.
  2. Herceptin: Targeted the HER2 protein in aggressive breast cancers. The story of Barbara Bradfield, one of the first patients to receive Herceptin, illustrates its remarkable effectiveness in HER2-positive breast cancer.
  3. Hormone Therapies: Tamoxifen for estrogen-receptor positive breast cancer demonstrated that understanding cancer's biology could lead to more targeted treatments with fewer side effects.

Prevention and Screening

Tobacco and Cancer

One of the most significant victories in cancer prevention came from identifying tobacco as a major carcinogen. Richard Doll and Austin Bradford Hill in Britain, and Ernst Wynder and Evarts Graham in America, independently demonstrated the link between smoking and lung cancer in the 1950s.

The tobacco industry fought back with misinformation campaigns, creating doubt about the smoking-cancer link through their "A Frank Statement" advertisement and establishing the Tobacco Industry Research Committee.

Other Preventable Causes

Scientists discovered additional preventable causes including asbestos exposure (mesothelioma), hepatitis B virus (liver cancer), and Helicobacter pylori bacteria (stomach cancer).

Early Detection

Secondary prevention through screening became another important strategy:

  • The Pap smear, developed by George Papanicolaou, could identify precancerous cervical lesions
  • Mammography for breast cancer was validated through the Malmö Mammographic Screening Study, demonstrating a 20-30% reduction in mortality for women aged 55-70

The Political Movement Against Cancer

Mary Lasker and Advocacy

A political movement gained momentum led by Mary Lasker, who lost her husband to colon cancer in 1952. Working with Sidney Farber, she:

  • Created public awareness campaigns
  • Transformed the American Cancer Society into a powerful fundraising machine
  • Lobbied Congress for increased federal funding
  • Used the moon landing as an analogy for what could be achieved ("a moon shot for cancer")

The National Cancer Act of 1971

These advocacy efforts culminated in the National Cancer Act of 1971, signed by President Nixon, which dramatically increased funding for cancer research and established comprehensive cancer centers.

This "War on Cancer" framing reflected both the success of early chemotherapy in specific cancers and the emerging theory that viruses caused most cancers—ideas that would later require significant revision.

Patient Advocacy and Access

Patient activists fought for access to experimental therapies. Breast cancer advocates like Marti Nelson and organizations like the Breast Cancer Action project pressured pharmaceutical companies to provide access to promising drugs before formal FDA approval.

When Genentech initially limited access to Herceptin clinical trials, breast cancer activists staged protests at their headquarters, forcing the company to create an expanded access program—representing a shift "from running trials ON breast cancer patients to running trials WITH breast cancer patients."

The Ongoing Battle

The Red Queen's Race

Mukherjee uses Lewis Carroll's metaphor to describe cancer treatment—we must keep running just to stay in place. Even with targeted therapies, cancer cells eventually develop resistance, requiring new drugs to overcome new mutations.

Jerry Mayfield's case exemplifies this challenge. His chronic myeloid leukemia initially responded to Gleevec but eventually developed resistance. Scientists then developed dasatinib, a second-generation drug that could overcome Gleevec resistance, illustrating the ongoing cycle of treatment, resistance, and new treatment development.

Measuring Progress

Cancer mortality declined for fifteen consecutive years between 1990 and 2005—dropping approximately 1% annually. This progress resulted from multiple approaches:

  • Prevention (reduced smoking)
  • Early detection (mammography, colonoscopy, Pap smears)
  • Improved treatments (chemotherapy, hormonal therapy, targeted drugs)

Breast cancer mortality, for example, fell by 24% during this period, with statistician Donald Berry determining that both early detection through mammography and improved treatment with adjuvant chemotherapy contributed equally—demonstrating that no single approach could conquer cancer.

Philosophical Reflections

Mukherjee reflects on cancer's paradoxical nature—it is both foreign yet intrinsically part of ourselves. He proposes that complete eradication may be impossible, as cancer is "stitched into our genome." However, substantial progress means that while "death in old age is inevitable, death before old age is not."

A thought experiment involving Atossa, the Persian queen with breast cancer from 500 BCE, illustrates this progress. If transported through time with the same cancer, her treatment options and survival chances would dramatically improve in each era, culminating with modern targeted therapies that might add decades to her life.

Conclusion: From Universal Solutions to Personalized Approaches

The narrative of cancer treatment has evolved from viewing cancer as a single disease requiring universal solutions to recognizing it as hundreds of genetically distinct diseases requiring personalized approaches based on their specific molecular drivers.

Through this journey, Mukherjee weaves powerful human stories—from Sidney Farber's pioneering leukemia patients to Germaine Berne's battle with a rare gastrointestinal stromal tumor to Barbara Bradfield's remarkable response to Herceptin—reminding readers that behind every scientific breakthrough are real patients whose lives hang in the balance.

The Emperor of All Maladies ultimately presents cancer as not just a disease to be conquered but as a lens through which we can understand our own biology, mortality, and the remarkable ingenuity of scientific progress in the face of one of humanity's oldest and most formidable foes.